Decoy Therapeutics Inc.
Close on Oct 19, 2026
- Market cap
- $622.40K
- P/E (TTM)
- –
- Dividend yield
- –
About Decoy Therapeutics
Pharmaceutical Preparations, SIC 2834
Decoy Therapeutics Inc. is a pre-clinical stage biotechnology company dedicated to engineering and advancing a pipeline of novel peptide conjugate therapeutics. Using its proprietary IMP³ACT platform, the company combines artificial intelligence, machine learning, and rapid synthesis methods to create designable multi-antiviral candidates that target conserved mechanisms across enveloped viruses. Its primary development programs concentrate on infectious diseases and oncology, including a lead pan-coronavirus prophylactic nasal spray and a broad-spectrum respiratory antiviral covering influenza, respiratory syncytial virus, and coronavirus. The company designs its therapies for high-risk, immunocompromised patient populations and healthcare providers.
The company operates without commercial products or product sales revenue, conducting early-stage research and preclinical studies. Its programs are structured to address widespread viral respiratory threats across the United States and Europe, with clinical development plans aimed at international regulatory authorities including the United States Food and Drug Administration. The provided text contains no information regarding the company's specific headquarters location.
Summary of the business section of Decoy Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Decoy Therapeutics Inc.
- Headquarters
- Houston, TX
- Address
- 2450 Holcombe Blvd, Suite J-608 77021
- Phone
- (346) 772-0346
- Employees
- 11, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Houston, Texas
Stock & identifiers
- Ticker
- DCOY
- Exchange
- Nasdaq
- IPO date
- Jan 29, 2015
- Shares outstanding
- 1M, Aug 12, 2026
- Public float
- $1.90M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-12 reverse, Mar 9, 2026; 1-for-15 reverse, Aug 18, 2025; 1-for-15 reverse, Aug 15, 2025; 1-for-8 reverse, Jun 17, 2024; 1-for-8 reverse, Jun 14, 2024; 1-for-25 reverse, Oct 17, 2022; 1-for-25 reverse, Oct 14, 2022; 1-for-25 reverse, Jul 22, 2019
- SEC CIK
- 1615219
- CUSIP
- 79400X602
- ISIN
- US79400X6022
- LEI
- 549300CLUMLZXIHU7X22
- EIN
- 46-5087339
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Frederick Pierce Ii | Chief Executive Officer | 34,844 |
| Mark J. Rosenblum | Chief Financial Officer | 11,363 |
| Peter Klaus Marschel | Chief Business Officer | 3,900 |
| Barbara Louise Hibner | Chief Scientific Officer | 4,216 |
| William K. McVicar | Director | 4,064 |
| Patricia G. Gauthier | Director | 2,000 |
| Jonathan I. Lieber | Director | 2,002 |
| Arnold C. Hanish | Director | 8,418 |
| Tess Burleson | Director | 2,002 |
| Paul Lammers | Director | 2,001 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $900.27K | $798.68K | $225.06K | $0 | – |
| FY2025 David Arthur | $106.23K | $106.22K | $225.06K | $0 | – |
| FY2025 Frederick Pierce | $225.04K | $124.49K | $225.06K | $0 | – |
| FY2025 Mark Rosenblum | $569.00K | $567.97K | $225.06K | $0 | – |
| FY2024 | $734.45K | $727.59K | $350.42K | $15 | – |
| FY2024 David Arthur | $734.45K | $727.59K | $350.42K | $15 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of March 20, 2026, we had eleven full-time employees.”
Corporate history
Events identified from SEC filings